September 26, 2026

mRNA-4157

Moderna Stock 2026: Phase 3 Cancer Vaccine Wins — Is the MRNA Rally Already Too Far?

Moderna’s Phase 3 melanoma trial with Merck met its primary and key secondary endpoints. MRNA now has real oncology proof, but Q2 revenue was only $0.1B and cash burn remains.

Mehr lesen